Clinical trials: insulin glargine
Diabetes Mellitus, Type 2
A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes Mellitus
Primary objective: To determine the optimal treatment algorithm for the clinical use of insulin glargine based on the incidence of severe hypoglycaemia.
- Trial name
- AT-LANTUS (NCT00399724)
- Testing
- Insulin glargine
- Volunteers
- 7,376 people
- Sponsor
- Sanofi
Type 2 Diabetes
Chronicare for Type 2 Diabetes (Chronicare-T2D)
This single-blind, single-center, randomized, controlled trial is designed to evaluate the utility of the Chronicare Disease Management Program in the management of subjects with T2D who are being treated with insulin glargine…
- Trial name
- CRX-T2D (NCT03997331)
- Testing
- CRx Health, Chronicare
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- QuiO
Diabetes Mellitus, Type 1
A Study for Patients With Type 1 Diabetes Mellitus
The purpose of the study is to compare the human insulin inhalation powder plus insulin glargine with injected insulin (regular human insulin or insulin lispro) plus insulin glargine on lowering the blood sugar level.
- Trial name
- NCT00447213
- Testing
- Insulin glargine, Human Insulin Inhalation Powder, Injectable Insulin
- Where
- 5 sites in Japan, Taiwan
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
Evaluation of Glycemic Changes During Exercise in Children With Type 1 Diabetes
The objectives of the study are: 1) to evaluate the effects of moderate exercise on SG evolution without insulin dose modification in patients with T1D under continuous subcutaneous insulin infusion (CSII) and multiple daily…
- Trial name
- TREAD-DIAB (NCT02824510)
- Testing
- Algorithmic changes in insulin therapy., Treadmill exercises, Insulin aspart, glargine and detemir
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Diabetes Mellitus, Type 2
Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial
This study was the extension of the LANTU_C_02761 study named EASIE and identified as NCT00751114 (core study comparing insulin glargine versus sitagliptin in insulin-naïve patients treated with metformin and not adequately…
- Trial name
- NCT00851903
- Testing
- Insulin Glargine, Sitagliptin, Metformin
- Where
- 16 sites in United States, Austria and 14 more
- Volunteers
- 112 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Trial to Investigate Efficacy and Usability of Published Best Practice to Control Glycaemia
The purpose of the study is to compare the efficacy of enhanced published best practice paper-based insulin titration protocol for glycaemic control in hospitalised patients with type 2 diabetes for the length of hospital stay.
- Trial name
- NCT01407289
- Testing
- Insulin Aspart, Insulin Glargine
- Where
- Austria
- Volunteers
- 74 people
- Sponsor
- Medical University of Graz
Stroke, Ischemic, Mild Cognitive Impairment
Dapagliflozin Effect in Cognitive Impairment in Stroke Trial
Background: Dementia is an international public health problem, affecting approximately 50,000,000 people worldwide in 2018 and will triple by 2050; furthermore, reaching an approximate cost of 4 billion dollars.
- Conditions
- Stroke, Ischemic, Mild Cognitive Impairment, Dementia, Vascular, Metabolic Syndrome
- Trial name
- DECIST (NCT05565976)
- Testing
- Dapagliflozin 10mg Tab, Statins (Cardiovascular Agents), Platelet Antiaggregant
- Where
- Mexico
- Volunteers
- 270 people
- Sponsor
- Jaime Daniel Mondragon
Diabetes, Diabetes Mellitus, Type 1
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of this trial is to compare two NN1250 (insulin degludec) formulations with each other and with insulin glargine, all in combination with…
- Trial name
- NCT00612040
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 33 sites in United States, Australia and 3 more
- Volunteers
- 178 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus
Insulin lispro is approved by the Food and Drug Administration (FDA) for the treatment of diabetes mellitus. Recombinant human hyaluronidase (rHuPH20) is approved by the FDA as an aid to the absorption and dispersion of other…
- Trial name
- NCT00883558
- Testing
- Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Halozyme Therapeutics
Type 2 Diabetes Treated With Insulin
Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus
Hyperglycemia affects 30-40% of hospitalized patients. Despite the fact that basal/bolus insulin therapy has been demonstrated to improve glycemic control and clinical outcomes in patients, achieving good glucose control remains…
- Trial name
- In-FI (NCT04460326)
- Testing
- Insulin glargine, NovoLog, Insulin Fiasp
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Boston Medical Center
Diabetes, Diabetes Mellitus, Type 2
Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to test if Insulin Detemir as add-on to current Oral Antidiabetic Drug treatment is at least as effective as Insulin Glargine as…
- Trial name
- NCT00283751
- Testing
- insulin detemir, insulin glargine
- Where
- 96 sites in United States, Austria and 5 more
- Volunteers
- 583 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2)
To compare in terms of HbA1c insulin naive patients with Type 2 Diabetes starting with insulin glargine on an algorithm with insulin naive patients starting with insulin glargine on the physician's standard practice.
- Trial name
- Malbec (NCT00627471)
- Testing
- Insulin Glargine
- Where
- Argentina
- Volunteers
- 9 people
- Sponsor
- Sanofi
Diabetic Patients With Gastrointestinal Cancer Undergoing Surgery and Receiving Parenteral Nutrition
Glargine Insulin vs.Continuous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN)
Hyperglycemia increases the risk of complications in surgical patients. Focus on poor glycemic control as a contributor to adverse outcomes in settings outside the intensive care unit (ICU) is often dismissed.
- Trial name
- GLUCOSE-in-PN (NCT02216799)
- Testing
- Glargine Insulin, Regular insulin
- Where
- Saudi Arabia
- Volunteers
- 61 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Diabetes Mellitus
Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus
Primary: To compare the efficacy and safety of Insulin Glulisine to Insulin Lispro in subjects with type 1 or type 2 diabetes mellitus. To compare the frequency of hypoglycemia of Insulin Glulisine to Insulin Lispro.
- Trial name
- NCT00467376
- Testing
- Insulin Glulisine, Lispro, Insulin Glargine
- Where
- China
- Volunteers
- 485 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
Glulisine + Lantus in Type I Patients
To evaluate the efficacy (in terms of change HbA1c from baseline to endpoint) and safety (in terms of adverse events, clinical chemistry, lipids, hematology) of insulin glulisine (HMR 1964) in subjects with type I diabetes…
- Trial name
- NCT00545337
- Testing
- Insuline glulisine
- Where
- Ukraine
- Volunteers
- 60 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes
The purpose of this study is to see what the effects of using one or two additional diabetes drugs (dapagliflozin and exenatide-LAR) are on blood sugar levels in patients who are taking insulin.
- Trial name
- Dexlar (NCT02811484)
- Testing
- Exenatide-LAR plus Dapagliflozin, Insulin Titration, Behavioral Therapy
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Type 2 Diabetes
Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells
In this trial, it will be studied whether early addition of the long acting insulin analogue Glargine is capable of increasing the number and differentiation of endothelial progenitor cells (EPC) in patients with type 2 diabetes…
- Trial name
- NCT00523393
- Testing
- Insulin Glargin, Human Insulin
- Where
- Germany
- Volunteers
- 75 people
- Sponsor
- Heidelberg University
Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine
Primary Objective: To demonstrate non-inferiority of SAR341402 versus NovoLog/NovoRapid in glycated hemoglobin A1c (HbA1c) change from baseline to Week 26 in participants with type 1 or type 2 diabetes mellitus (T1DM or T2DM)…
- Trial name
- GEMELLI1 (NCT03211858)
- Testing
- Insulin aspart, NovoLog/NovoRapid, Insulin glargine (HOE901)
- Where
- 82 sites in United States, Finland and 5 more
- Volunteers
- 597 people
- Sponsor
- Sanofi
Diabetes Mellitus (DM)
Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DM
Purpose: To compare efficacy and safety of traditional sliding scale insulin (SSI) versus modified 70/30 insulin versus modified basal plus supplemental scale /bolus insulin regimens for glycemic control in hospitalized diabetic…
- Trial name
- NCT01855243
- Testing
- regular insulin, 70/30 insulin, Glargine
- Where
- Egypt
- Volunteers
- 63 people
- Sponsor
- Cairo University
Type 2 Diabetes, Hyperglycemia
Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM)
The study is a prospective randomized study comparing safety and effectiveness of a basal-bolus regimen with glargine once daily and glulisine before meals, a basal plus regimen with glargine once daily and supplemental doses of…
- Trial name
- Basal-Plus (NCT00979628)
- Testing
- sliding scale regular insulin (SSRI), Basal Bolus, Basal Plus
- Where
- 5 sites in United States
- Volunteers
- 375 people
- Sponsor
- Guillermo Umpierrez, MD